Jaffetilchin Investment Partners LLC Sells 1,262 Shares of Amgen Inc. $AMGN

Jaffetilchin Investment Partners LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 23.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,095 shares of the medical research company’s stock after selling 1,262 shares during the period. Jaffetilchin Investment Partners LLC’s holdings in Amgen were worth $1,143,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. LPL Financial LLC lifted its stake in Amgen by 9.1% in the 1st quarter. LPL Financial LLC now owns 903,878 shares of the medical research company’s stock valued at $281,603,000 after purchasing an additional 75,636 shares during the last quarter. Shoker Investment Counsel Inc. boosted its position in Amgen by 3.2% in the first quarter. Shoker Investment Counsel Inc. now owns 10,508 shares of the medical research company’s stock valued at $3,274,000 after buying an additional 324 shares in the last quarter. Brio Consultants LLC bought a new stake in shares of Amgen during the first quarter worth $235,000. Finally, Portland Global Advisors LLC increased its holdings in shares of Amgen by 0.5% during the first quarter. Portland Global Advisors LLC now owns 23,876 shares of the medical research company’s stock worth $7,439,000 after buying an additional 121 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 over the last quarter. 0.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on AMGN. Citigroup raised their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Amgen in a report on Tuesday. Scotiabank initiated coverage on Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target on the stock. Bank of America upped their price objective on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Finally, UBS Group cut their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $320.86.

Amgen Stock Down 1.0%

Amgen stock opened at $334.30 on Tuesday. The firm has a market cap of $180.01 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.61 and a beta of 0.45. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $345.84. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a 50 day moving average price of $302.19 and a two-hundred day moving average price of $293.02.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Friday, November 21st. Amgen’s dividend payout ratio is 73.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.